Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Fusco

Hospitalist Hartford, CT Doctor of Osteopathy

NPI 1528404373 CMS profile 1600515

114 Woodland St, Department Of Medicine, Hartford, CT 06105

Open in the dashboard

General payments

$3,950

175 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Fusco of Hartford, CT is reported in the CMS Open Payments database as having received $3,950 across 175 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Hospitalist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $929 31
2024 General $799 35
2023 General $848 34
2022 General $596 31
2021 General $506 28
2020 General $131 8
2019 General $142 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Fusco
  • Hospitalist median
  • Middle half of Hospitalist
  • National median

In program year 2025, general payments to Joseph Fusco were reported at $929. Among 6,882 Hospitalist profiles paid that year, the median was $86 and the middle half received between $30 and $191.

Show as a table
Year Joseph Fusco Hospitalist median Middle half National median
2019 $142 $96 $28–$201 $163
2020 $131 $48 $19–$125 $114
2021 $506 $70 $23–$167 $132
2022 $596 $85 $27–$174 $149
2023 $848 $89 $30–$191 $160
2024 $799 $95 $29–$204 $164
2025 $929 $86 $30–$191 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $718 30 payments
  2. AstraZeneca Pharmaceuticals LP $440 27 payments
  3. E.R. Squibb & Sons, L.L.C. $432 22 payments
  4. Alexion Pharmaceuticals, Inc. $375 17 payments
  5. Mallinckrodt Hospital Products Inc. $367 9 payments
  6. Janssen Pharmaceuticals, Inc $302 15 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $269 12 payments
  8. Novartis Pharmaceuticals Corporation $208 11 payments
  9. Alnylam Pharmaceuticals Inc. $108 3 payments
  10. CSL Behring $86 3 payments
  11. Other $644 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,950 175 payments
Products named General payments · program years 2019–2025
  1. ELIQUIS Cardiovascular;Metabolic Disease $383 19 payments
  2. TERLIVAZ $367 9 payments
  3. VYNDAQEL $334 11 payments
  4. XARELTO $302 15 payments
  5. XIFAXAN $269 12 payments
  6. PAXLOVID $259 12 payments
  7. ULTOMIRIS $247 11 payments
  8. FARXIGA $224 14 payments
  9. ELIQUIS Cardiovascular $212 11 payments
  10. CAMZYOS $205 10 payments
  11. Other $1,618 75 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$43,606

Medicare's payments for the services billed

Medicare patients

177

Average age 76

Services billed

607

92 women, 85 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 55%
Heart failure 54%
Arthritis 54%
Ischemic heart disease 53%
Chronic kidney disease 47%
Diabetes 46%
Atrial fibrillation 46%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $116
$116 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $97
$97 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $47
  • PFIZER INC. $18
$65 — —
VYNDAQEL
  • PFIZER INC. $63
$63 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $60
$60 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

175 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hospitalist in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record